Jay Johnson, DO
Family Medicine · Des Moines, IANPI 1497715262
Payments from drug & device makers
Across 100 payments — averaging $12.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$375
- Novo Nordisk$276
- AstraZeneca$101
- Johnson & Johnson$89
- Boehringer Ingelheim$87
- Amgen$62
- plus $274 from 10 others
What the payments were for
- Food & beverage$1,264100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $375 |
| Novo Nordisk | 20 | $276 |
| AstraZeneca | 7 | $101 |
| Johnson & Johnson | 6 | $89 |
| Boehringer Ingelheim | 6 | $87 |
| Amgen | 5 | $62 |
| Pfizer | 4 | $62 |
| GSK | 4 | $54 |
| Shire North American Group Inc | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Merck | 2 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $12 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$1,264 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $82,628 |
| TrulicityDulaglutide | 41 | $72,848 |
| MounjaroTirzepatide | 38 | $70,493 |
| Xigduo XrDapaglifloz Propaned/Metformin | 56 | $64,604 |
| RybelsusSemaglutide | 26 | $49,097 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $36,212 |
| EliquisApixaban | 30 | $35,801 |
| FarxigaDapagliflozin Propanediol | 23 | $30,232 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $28,251 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 21 | $27,673 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $26,409 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $24,999 |
| XareltoRivaroxaban | 14 | $23,592 |
| JardianceEmpagliflozin | 24 | $21,287 |
| JanuviaSitagliptin Phosphate | 18 | $19,950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $276 | $131,72575 claims |
| Boehringer IngelheimSynjardy Xr, Stiolto Respimat, Jardiance | $87 | $75,37065 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $54 | $67,85864 claims |
| MerckJanumet, Januvia, Janumet Xr, Dulera | $23 | $67,45873 claims |
| PfizerEliquis | $62 | $35,80130 claims |
| AstraZenecaFarxiga | $101 | $30,23223 claims |
| Johnson & JohnsonXarelto | $89 | $23,59214 claims |
| AbbVieLinzess | $375 | $6,38914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Des Moines
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Dylan LoweDes Moines$105K
- Lisa KlockDes Moines$9K
- Kristin GisselmanDes Moines$8K
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.